EMD Millipore

Merck Millipore, celares collaborate

Monday, October 5, 2015

Merck Millipore, the life science business of German-based Merck, is collaborating with celares, a privately owned biopharmaceuticals company, to provide pegylation services to customers developing protein-based therapeutics and biosimilars. The new service offering enabled by the collaboration includes feasibility studies, process and analytical development and scale-up from milligram to gram quantities required for pilot and subsequent commercial scale.

[Read More]

EMD Millipore inks agreement with Precision Biologics

Monday, February 2, 2015

EMD Millipore, the life science business of Merck of Darmstadt, Germany, has announced an agreement for providing upstream process development services for Precision Biologics, a Texas-based clinical-stage biotechnology company, to advance a preclinical monoclonal antibody. The antibody, NEO-201, binds to a tumor-specific antigen found in several forms of cancer, offering therapeutic potential across multiple cancer types, including colorectal, lung, ovarian and pancreatic, an especially deadly cancer with limited treatment options.

[Read More]

North Shore InnoVentures receives $1.65M from Massachusetts Life Sciences Center

Monday, March 31, 2014

North Shore InnoVentures (NSIV), a New England technology incubator and business accelerator, has received a capital grant of $1.65 million from the Massachusetts Life Sciences Center (MLSC). The grant will allow NSIV to expand its current laboratory facilities over the next three years and purchase advanced analytical instrumentation. This grant is part of a larger $5 million award to the Life Sciences Consortium of the North Shore (LSCNS), consisting of Endicott College, Gordon College, North Shore InnoVentures, North Shore Community College and Salem State University, that will fund major lab/facility and equipment upgrade projects at the member institutions and organizations.

[Read More]